Rory B. Riggs - 23 Jun 2024 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Role
Director
Signature
/s/ Lawrence J. Hineline, Attorney-in-fact
Issuer symbol
ITCI
Transactions as of
23 Jun 2024
Net transactions value
+$6.66
Form type
4
Filing time
25 Jun 2024, 18:04:54 UTC
Previous filing
18 Jun 2024
Next filing
02 Jul 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITCI Common Stock Options Exercise +1,567 +1.6% 101,062 23 Jun 2024 Direct F1
transaction ITCI Common Stock Options Exercise $337,200 +20,000 +20% $16.86 121,062 24 Jun 2024 Direct F2
transaction ITCI Common Stock Sale $337,193 -4,462 -3.7% $75.57 116,600 24 Jun 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITCI Restricted Stock Units Options Exercise $0 -1,567 -100% $0.000000* 0 23 Jun 2024 Common Stock 1,567 Direct F1, F3
transaction ITCI Stock Option (right to buy) Options Exercise $0 -20,000 -100% $0.000000* 0 24 Jun 2024 Common Stock 20,000 $16.86 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock.
F2 On June 24, 2024, the reporting person exercised options to purchase 20,000 shares of common stock that are expiring on June 30, 2024 and the issuer retained 4,462 shares of common stock to pay the exercise price of the options.
F3 On June 23, 2023, the reporting person was granted 1,567 restricted stock units, which vested on the first anniversary of the grant date (June 23, 2024).
F4 This option was granted on June 30, 2014 and will expire on June 30, 2024. All shares underlying this option have vested.